Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Athersys, Inc.    ATHX

Delayed Quote. Delayed  - 09/27 10:00:00 pm
1.96 USD   --.--%
12:31p Athersys Receives FDA Agreement Under Special Protocol Assessment..
09/12 Athersys Announces Acceptance by PMDA of Clinical Trial Notificat..
08/24 ATHERSYS : Erlanger experiment will attempt to restore stroke victim..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Athersys, Inc. : Analysis Reports On Active NASDAQ Stocks: (NASDAQ: ATHX), (NASDAQ: PDLI)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/18/2013 | 07:40am CEST

New York (April 18th, 2013) - Athersys, Inc. (NASDAQ: ATHX) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Athersys' application to expand its ongoing Phase 2 study evaluating the administration of MultiStem(R) therapy to patients who have suffered an ischemic stroke. Enrollment at United Kingdom sites is expected to commence following final Ethics Committee review and the completion of final preparations at participating clinical centers.

"The MHRA authorization will enable us to bring several leading United Kingdom stroke centers into the study, which will help us to speed the completion of the stroke clinical trial," said Dr. Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys. "The authorization is also noteworthy as it marks the initiation of MultiStem clinical development activity in the United Kingdom."

Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine.

Get everything traders and investors are looking for when trading ATHX here:

http://stockreportdaily.com/market-scan/?symbol=ATHX


PDL BioPharma Inc. (NASDAQ:PDLI) traded at $ 7.45 in the last session, which is 0.00 (0.00%). The stock has a Range of 7.31 - 7.46. The stock has a 52 week low and high of 6.09 - 8.43 respectively. The stock has a Market Cap of 1.04B. The stock traded a volume of 1.66M. The stock has a 30 day average volume of 1.81M.

In trading on Wednesday, shares of PDL BioPharmaInc (PDLI) crossed below their 200 day moving average of $7.32, changing hands as low as $7.31 per share.

PDL BioPharma, Inc. (PDL) is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014.

Find out more on PDLI here:

http://stockreportdaily.com/market-scan/?symbol=PDLI

ABOUT US:

Stockreportdaily.com issues momentum alerts on stocks that can provide gains to day traders. Stockreportdaily.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. Stockreportdaily.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Stockreportdaily.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Stockreportdaily.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www. Stockreportdaily.com

Disclosure: Stockreportdaily.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Stockreportdaily.com website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit; http://www.Stockreportdaily.com/disclaimer/

Contact Info:
George Fitz
Stock Report Daily
info@Stockreportdaily.com
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ATHERSYS, INC.
12:33p ATHERSYS, INC / NEW : Other Events, Financial Statements and Exhibits (form 8-K)
12:31p Athersys Receives FDA Agreement Under Special Protocol Assessment for Phase 3..
09/12 ATHERSYS : Announces Acceptance by PMDA of Clinical Trial Notification
09/12 ATHERSYS, INC / NEW : Other Events, Financial Statements and Exhibits (form 8-K)
09/12 Athersys Announces Acceptance by PMDA of Clinical Trial Notification in Japan..
08/24 ATHERSYS : Erlanger experiment will attempt to restore stroke victims' mobility
08/10 ATHERSYS : reports 2Q loss
08/09 ATHERSYS : NEW Management's Discussion and Analysis of Financial Condition and R..
08/09 ATHERSYS, INC / NEW : Results of Operations and Financial Condition, Financial S..
08/09 Athersys Reports Second Quarter 2016 Results
More news
Sector news : Bio Therapeutic Drugs
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07:42a Athersys receives FDA agreement under SPA for Phase 3 study of Multistem trea..
09/13 All Systems Go On Athersys Pivotal Stem Cell Stroke Trial In Japan - Explorin..
08/09 Athersys' (ATHX) CEO Gil Van Bokkelen on Q2 2016 Results - Earnings Call Tran..
08/09 Athersys beats by $0.02, beats on revenue
08/08 Notable earnings after Tuesday?s close
Advertisement
Financials ($)
Sales 2016 16,9 M
EBIT 2016 -17,0 M
Net income 2016 -18,2 M
Debt 2016 9,09 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 10,4x
EV / Sales 2017 27,0x
Capitalization 167 M
More Financials
Chart ATHERSYS, INC.
Duration : Period :
Athersys, Inc. Technical Analysis Chart | ATHX | US04744L1061 | 4-Traders
Full-screen chart
Technical analysis trends ATHERSYS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 7,00 $
Spread / Average Target 257%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gil van Bokkelen Chairman & Chief Executive Officer
William B. J. Lehmann President, Chief Operating Officer & Secretary
Laura K. Campbell Principal Accounting Officer & SVP-Finance
John J. Harrington Director, Chief Scientific Officer & Executive VP
Lorin Jeffry Randall Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ATHERSYS, INC.90.29%167
AMGEN, INC.5.73%129 863
GILEAD SCIENCES, INC.-21.68%106 391
CELGENE CORPORATION-10.32%82 402
REGENERON PHARMACEUTIC..-22.37%42 552
VERTEX PHARMACEUTICALS..-29.17%21 876
More Results